Literature DB >> 26039208

Immunotherapy for viral and fungal infections.

H Einsele1, J Löffler1, M Kapp1, L Rasche1, S Mielke1, U G Grigoleit1.   

Abstract

Allogenic stem cell transplantation (allo-SCT) represents the only curative option for several hematological malignancies. Due to a delayed and dysfunctional immunological recovery infectious complications and residual tumor cells following allo-SCT are still major causes of failure of this procedure. Here we discuss the most common infectious complications of allo-SCT and describe current and future strategies to prophylaxe or treat these complications using novel immunotherapeutic strategies.

Entities:  

Mesh：

Year:  2015        PMID： 26039208     DOI： 10.1038/bmt.2015.96

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  44 in total

1.  A single naive CD8+ T cell precursor can develop into diverse effector and memory subsets.

Authors:  Christian Stemberger; Katharina M Huster; Martina Koffler; Florian Anderl; Matthias Schiemann; Hermann Wagner; Dirk H Busch
Journal:  Immunity       Date:  2007-12       Impact factor: 31.745

2.  Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy.

Authors:  Christian Stemberger; Patricia Graef; Marcus Odendahl; Julia Albrecht; Georg Dössinger; Florian Anderl; Veit R Buchholz; Georg Gasteiger; Matthias Schiemann; Götz U Grigoleit; Friedhelm R Schuster; Arndt Borkhardt; Birgitta Versluys; Torsten Tonn; Erhard Seifried; Hermann Einsele; Lothar Germeroth; Dirk H Busch; Michael Neuenhahn
Journal:  Blood       Date:  2014-05-22       Impact factor: 22.113

3.  Disparate individual fates compose robust CD8+ T cell immunity.

Authors:  Veit R Buchholz; Michael Flossdorf; Inge Hensel; Lorenz Kretschmer; Bianca Weissbrich; Patricia Gräf; Admar Verschoor; Matthias Schiemann; Thomas Höfer; Dirk H Busch
Journal:  Science       Date:  2013-03-14       Impact factor: 47.728

4.  Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection.

Authors:  H Einsele; H Hebart; C Kauffmann-Schneider; C Sinzger; G Jahn; P Bader; T Klingebiel; K Dietz; J Löffler; C Bokemeyer; C A Müller; L Kanz
Journal:  Bone Marrow Transplant       Date:  2000-04       Impact factor: 5.483

Review 5.  EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT.

Authors:  L Rasche; M Kapp; H Einsele; S Mielke
Journal:  Bone Marrow Transplant       Date:  2013-07-08       Impact factor: 5.483

6.  Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation.

Authors:  Tobias Feuchtinger; Julia Lücke; Klaus Hamprecht; Celine Richard; Rupert Handgretinger; Michael Schumm; Johann Greil; Thomas Bock; Dietrich Niethammer; Peter Lang
Journal:  Br J Haematol       Date:  2005-02       Impact factor: 6.998

7.  Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants.

Authors:  Georg Rauser; Hermann Einsele; Christian Sinzger; Dorothee Wernet; Gabriele Kuntz; Mario Assenmacher; John D M Campbell; Max S Topp
Journal:  Blood       Date:  2003-12-11       Impact factor: 22.113

8.  Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation.

Authors:  Tobias Feuchtinger; Celine Richard; Stefanie Joachim; Michael H Scheible; Michael Schumm; Klaus Hamprecht; David Martin; Gerhard Jahn; Rupert Handgretinger; Peter Lang
Journal:  J Immunother       Date:  2008 Feb-Mar       Impact factor: 4.456

9.  CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.

Authors:  Francisco M Marty; Drew J Winston; Scott D Rowley; Estil Vance; Genovefa A Papanicolaou; Kathleen M Mullane; Thomas M Brundage; Alice T Robertson; Susan Godkin; Hervé Momméja-Marin; Michael Boeckh
Journal:  N Engl J Med       Date:  2013-09-26       Impact factor: 91.245

10.  Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies.

Authors:  Holger Hebart; Claudia Bollinger; Paul Fisch; Jacqueline Sarfati; Christoph Meisner; Manuela Baur; Jürgen Loeffler; Michel Monod; Jean-Paul Latgé; Hermann Einsele
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113
View more
  5 in total

1.  Sepsis in the era of data-driven medicine: personalizing risks, diagnoses, treatments and prognoses.

Authors:  Andrew C Liu; Krishna Patel; Ramya Dhatri Vunikili; Kipp W Johnson; Fahad Abdu; Shivani Kamath Belman; Benjamin S Glicksberg; Pratyush Tandale; Roberto Fontanez; Oommen K Mathew; Andrew Kasarskis; Priyabrata Mukherjee; Lakshminarayanan Subramanian; Joel T Dudley; Khader Shameer
Journal:  Brief Bioinform       Date:  2020-07-15       Impact factor: 11.622

Review 2.  How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation.

Authors:  Alpana Waghmare; Janet A Englund; Michael Boeckh
Journal:  Blood       Date:  2016-03-11       Impact factor: 22.113

3.  Differential Macrophage Polarization from Pneumocystis in Immunocompetent and Immunosuppressed Hosts: Potential Adjunctive Therapy during Pneumonia.

Authors:  Vijayalakshmi Nandakumar; Deanne Hebrink; Paige Jenson; Theodore Kottom; Andrew H Limper
Journal:  Infect Immun       Date:  2017-02-23       Impact factor: 3.441

4.  Prescribing Pattern of Antifungal Medications at a Tertiary Care Hospital in Oman.

Authors:  Khalid A Al Balushi; Mohammed A Alzaabi; Fatma Alghafri
Journal:  J Clin Diagn Res       Date:  2016-12-01

5.  Novel treatment of severe combined immunodeficiency utilizing ex-vivo T-cell depleted haploidentical hematopoietic stem cell transplantation and CD45RA+ depleted donor lymphocyte infusions.

Authors:  Nicholas Brodszki; Dominik Turkiewicz; Jacek Toporski; Lennart Truedsson; Josefina Dykes
Journal:  Orphanet J Rare Dis       Date:  2016-01-15       Impact factor: 4.123
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.